Amniotic Fluid Embolism
Amniotic Fluid Embolism (AFE) is an uncommon, catastrophic obstetric emergency. The frequency of AFE is 2-7 cases per 100,000 births. It is responsible for approximately 10-15% of maternal deaths in developed countries. If AFE occurs prior to delivery, the neonatal mortality rate is estimated to be 10-50%. Many surviving neonates suffer neurologic impairment. Neurologic impairment is also common in maternal survivors, particularly those who suffer associated cardiac arrest. Although the pathophysiology of AFE is not known, it has been suggested that entry of amniotic fluid into the maternal circulation activates inflammatory mediators causing an anaphylactoid response.
Although AFE occurs most commonly during labor and delivery or the immediate postpartum period, it has been reported to occur as late as 48 hours postpartum. AFE should be considered in the differential diagnosis of sudden cardiorespiratory collapse in the laboring or recently delivered woman. Patients may also present with acute severe consumptive coagulopathy without cardiorespiratory symptoms. Risk factors for AFE include advanced maternal age, multiparity, pre-eclampsia, eclampsia, diabetes mellitus, and polyhydramnios or other uterine over-distention. Labor abnormalities associated with an increased risk of AFE include precipitous labor, induction of labor, placental abruption, cervical laceration, and uterine rupture.
Three phases have been described during the clinical course of AFE. The first phase involves pulmonary and systemic hypertension with resultant severe pulmonary vasoconstriction, characterized by respiratory distress and hypoxemia, leading to altered mental status followed by hemodynamic collapse. The second phase involves decreased systemic vascular resistance and left ventricular stroke work index. The third phase is characterized by lung injury and coagulopathy, which may include disseminated intravascular coagulation (DIC). The tissue injury and end organ system failure seen in AFE with pulmonary vascular constriction often lead to pulmonary hypertension, right-sided heart failure, and global myocardial depression.
The management of AFE includes early recognition and prompt multidisciplinary management and other specialists including anesthesia, respiratory therapy, critical care, and MFM. Massive blood transfusion protocols should be activated. An operating room, interventional radiology team, and the Intensive Care Unit should be made available. Laboratory assessment is not necessary to make the diagnosis, but arterial blood gas analysis, serial blood counts, and coagulation studies may help guide resuscitation. An arterial catheter to monitor blood pressure can be helpful. The management should focus on oxygenation and circulatory support with blood products, judicious use of intravenous fluids, vasopressors, and if necessary, cardiopulmonary bypass. If AFE occurs prior to delivery, maternal resuscitation is aided by expeditious delivery.
Control of hemorrhage and correction of coagulopathy should be the goal of replacement therapy of blood products, with the possible use of recombinant factor VII if needed. Hysterectomy may be required to control hemorrhage. Support of maternal oxygenation often requires high oxygen flow rate and invasive mechanical ventilation with increasing levels of oxygen and increased positive end-expiratory pressures. The goal of therapy is to limit hypoxemia and hypotension to prevent ischemic consequences such as brain injury, acute renal damage, and myocardial ischemia.
Dean LS, Rogers RP 3rd, Harley RA, Hood DD. Case scenario: amniotic fluid embolism. Anesthesiology. 2012 Jan;116(1):186-92. doi: 10.1097/ALN.0b013e31823d2d99.
Cunningham F, Leveno KJ, Bloom SL, et al, Obstetrical Hemorrhage. Williams Obstetrics, 25e New York, NY: McGraw-Hill; 2018. Chapter 41.
Society for Maternal-Fetal Medicine (SMFM), Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol. 2016 Aug;215(2):B16-24. doi: 10.1016/j.ajog.2016.03.012. Epub 2016 Mar 14.
Initial Approval: April 2013; Revised: September 2015, Reaffirmed March 2018, Revised November 2018, Reaffirmed July 2020, Revised January 2022
********** Notice Regarding Use ************
The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. (“SASGOG”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high-quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. SASGOG reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. SASGOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither SASGOG nor its respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2022 The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.
Back to Search Results